Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded the Kenneth B. Schwartz Center. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to the caregivers, and sustenance to the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers and gain insight and support from fellow staff members. We tell the story of one physician with incurable non-small cell lung cancer (NSCLC) who had an unexpectedly favorable response to an experimental treatment while receiving it as a part of his palliative care. His unique insight provides an opportunity to elucidate some of the issues that arise from living both as a patient-caregiver and as a cancer "surpriser." When caregivers face their own cancer, their reflections as patient-caregivers offer an internal perspective on the illness experience and help us as fellow caregivers to better understand and support all patients who face serious illnesses, both those who are colleagues and those who are not. Just like any patient with cancer, patient-caregivers experience the dramatic changes in health, daily life, and perspective that come with serious illness. Within the context of a life-threatening illness, caregiver-patients and their families search for new meaning as they face an uncertain future and address the issues of life and death. In addition to such processes, patient-caregivers with cancer also find that their own medical knowledge and their colleagues' reactions shape their experiences and to an extent separate them from those of other patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1634/theoncologist.8-1-108 | DOI Listing |
Radiol Adv
January 2025
Department of Radiology, Duke University Medical Center, Durham, NC 27710, United States.
Purpose: To assess agreement between CT volumetry change classifications derived from Quantitative Imaging Biomarker Alliance Profile cut-points (ie, QIBA CTvol classifications) and the Response Evaluation Criteria in Solid Tumors (RECIST) categories.
Materials And Methods: Target lesions in lung, liver, and lymph nodes were randomly chosen from patients in 10 historical clinical trials for various cancers, ensuring a balanced representation of lesion types, diameter ranges described in the QIBA Profile, and variations in change magnitudes. Three radiologists independently segmented these lesions at baseline and follow-up scans using 2 software tools.
Open Heart
January 2025
Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.
Introduction: Data on the characteristics and outcomes of pregnancy and among patients with Fontan physiology are limited. We aimed to evaluate the immediate and long-term outcomes among these patients who were followed at our centre.
Methods: We included adult patients who had undergone Fontan surgery for congenital heart disease and were pregnant between 1994 and 2021.
Chemistry
January 2025
Centre CEA Paris-Saclay: Commissariat a l'Energie Atomique et aux Energies Alternatives Centre de Saclay, IRAMIS Institute, CEA - Saclay, 91190, Gif-Sur-Yvette, FRANCE.
The Schwartz's reagent Cp2Zr(H)Cl is a well known stoichiometric reagent for the reduction of unsaturated organic molecules but it has rarely been used in catalytic transformations. Herein, we describe the reduction of a variety of organic carbonates using the catalyst Cp2Zr(H)Cl in combination with Me(MeO)2SiH (DMMS) as reductant. This method was further applied to the reductive depolymerization of some polycarbonate materials and yielded silylated alcohols and diols in mild conditions.
View Article and Find Full Text PDFCrit Care Explor
January 2025
Division of Cardiovascular Critical Care Medicine, Department of Cardiology, Boston Children's Hospital, Boston, MA.
Background: Accurate assessment of oxygen delivery relative to oxygen demand is crucial in the care of a critically ill patient. The central venous oxygen saturation (Svo) enables an estimate of cardiac output yet obtaining these clinical data requires invasive procedures and repeated blood sampling. Interpretation remains subjective and vulnerable to error.
View Article and Find Full Text PDFAm J Cardiol
January 2025
Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA.
Lipid-lowering therapy (LLT) is the cornerstone for secondary prevention of atherosclerotic cardiovascular disease (ASCVD), yet many patients exhibit low adherence to therapy and fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. This retrospective cohort study used 2 nationally representative administrative closed claims databases (PharMetrics® Plus and Medicare Fee-for-Service [FFS] Research Identifiable Files) to identify commercial (C) and Medicare (M) enrollees with ASCVD between 2014-2019. Patients were stratified by exposure to statin therapy, ezetimibe and proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9i mAb) regimens.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!